Sun Pharmaceutical, which is growing its dermatology and ophthalmic specialty business in the US will spend $460 million on R&D.
Companies asked to give data for three batches instead of one; move may lead to significant rise in development cost of generics
Novartis said it is partnered with generic drugmaker Lupin Ltd to sell the drug in India
Revival in domestic business should also help overall revenue growth.
The combined sales of the branded versions of the products in the US is about $3.5 billion.
The FMCG index gained more than 1% on the back of stellar gains in ITC.
The list acknowledges the 'inroads women are making in the business world'.
Ajit Mishra, vice president, Research, Religare Broking, answers your queries.
Shree Cement beats ACC in market value, Lupin ahead of Dr Reddy's Labs
Data also show that several other leading domestic pharma companies have recalled their products from the US
The Indian Pharmaceutical Alliance has approached regulator for a dialogue to understand the concern raised by it
This is to take head on big American pharmaceutical giants, which in the recent past had launched a strong anti-India campaign against efforts of such companies to provide affordable health care not only to people in India, but also in the third world countries.
Currently, the govt directly caps prices of 348 formulations at the average price of all medicines in a particular segment with at least 1% market share
Under MRA, Japan is to recognise Indian medical degrees and treat the country's doctors and other medical personnel on par with its own.
Asia's falling stocks have triggered an exodus of funds from the region.
.jpg)
In a letter to health minister Harsh Vardhan, the Indian Pharmaceutical Alliance, an industry body representing leading pharma companies, including Sun Pharma, Lupin, Dr Reddy's Labs, Cadila Health and Glenmark, stressed the need for an out-of-court settlement with health activists fighting for the rights of clinical trial participants.
Earning woes drag markets lower; TCS, HUL lead fall.
The calculation excludes cross-holding of listed group cos in each other.
In a surprise announcement in April, Sun and Ranbaxy -- at that time owned by Japan's Daiichi -- declared an all-stock deal to create India's largest and world's fifth-largest drugmaker in an over $4 billion deal.
Ajit Mishra, vice president, Research, Religare Broking, answers your queries.
As on July 31, the valuation of his shareholding in the company stood at Rs 9,830 crore.
This is a shift as until recent months, fund managers were reducing exposure to these sectors.
Sun Pharma stock has appreciated at 35% a year for 20 years
FIIs are looking at the long-term story and initiatives of Indian pharma companies to transform themselves into global entities.
The S&P BSE Sensex gained 115 points to end at 24,338 and the Nifty50 climbed 42 points to close at 7,404.
Besides opposing the suspension of three medicines, the sector has also questioned the process adopted by the government.
Index heavyweights ITC was the top gainer along with RIL and HDFC
The Delhi High Court on Friday stayed the ban on some fixed dose combination (FDC) drugs of Glaxo SmithKline, Wockhardt and Laboratories Griffon but said action against their sale could be taken in the absence of valid sale and marketing licence.
The 30-share Sensex ended higher by 177.46 points at 28,885.21 and the Nifty gained 63.90 points at 8,778.30.
Not much is heard or read about Sun Pharma's media-shy owner.
Experts say the stock market correction in recent times increases the risk-reward in favour of large-cap stocks.
Even smaller companies like Torrent Pharma and Alembic file five to 10 ANDAs every year.
Cipla, though late in changing its strategy for international markets, has in recent years taken an inorganic route for expansion.
n the broader market, both the BSE Midcap and Smallcap indices, were up 1.2% and 0.7% each.
The S&P BSE Sensex ended 80 points up at 23,789 while the Nifty50 closed at 7,235, up 24 points.
Govt bans brands with annual sales worth Rs 3,728 crore.
Markets in green tracking firm global cues.
Once tipped to emerge as the biggest exporter, the pharmaceutical industry is yet to acquire the scale of those in software services, says Krishna Kant.
Sensex climbs higher on favourable global cues.
© 2026 Rediff.com - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances